Oral Signs of Viral Disease

  • Danielle N. Brown
  • Ramya KolliparaEmail author
  • Stephen Tyring


Viral disease of the soft tissues of the mouth, oral pharynx, and salivary glands is often encountered in practice in both children and adults. The clinical manifestations and implications dramatically vary depending on the specific virus involved. It can be difficult to distinguish between oral viral disease manifestations; however, subtle distinguishing features may facilitate differentiation. This chapter discusses the epidemiology, etiology, pathogenesis, differential diagnosis, diagnostic studies, and treatment for oral manifestations of viral diseases.


Oral Virus Herpes Varicella Hand, foot, and mouth disease Herpangina Molluscum HPV EBV HIV 


  1. 1.
    Smith J, Robinson N. Age specific prevalence of infection with herpes simplex virus types 2 and I: a global review. J Infect Dis. 2002;186(Suppl 1):3–28.Google Scholar
  2. 2.
    Fatahzadeh M. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis and management. J Am Acad Dermatol. 2007;57(5):737–63.PubMedGoogle Scholar
  3. 3.
    Roizman B. The organization of the herpes simplex virus genome. Ann Rev Genet. 1979;13:25–7.PubMedGoogle Scholar
  4. 4.
    Arduino P, Porter S. Herpes simplex virus type 1 infection: overview on relevant clinico-pathologic features. J Oral Pathol Med. 2008;37:107–21.PubMedGoogle Scholar
  5. 5.
    Stoopler E. Oral herpetic infections (HSV 1-8). Dent Clin N Am. 2005;49(1):15–29.PubMedGoogle Scholar
  6. 6.
    Lynch D. Oral viral infections. Clin Dermatol. 2000;18(5):619–28.PubMedGoogle Scholar
  7. 7.
    Simmons A. Clinical manifestations and treatment considerations of herpes simplex virus infection. J Infect Dis. 2002;186(Suppl 1):71–7.Google Scholar
  8. 8.
    Eisen D. The clinical characteristics of intraoral herpes simplex virus infections in 52 immunocompetent patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86:432–7.PubMedGoogle Scholar
  9. 9.
    Leflore S, Anderson P, Fletcher C. A risk-benefit evaluation of acyclovir for the treatment and prophylaxis of herpes simplex infections. Drug Saf. 2000;23(2):131–42.PubMedGoogle Scholar
  10. 10.
    Brady R, Bernstein D. Treatment of herpes simplex infections. Antivir Res. 2004;61:73–81.PubMedGoogle Scholar
  11. 11.
    Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–9.PubMedGoogle Scholar
  12. 12.
    Oxman M, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84.PubMedGoogle Scholar
  13. 13.
    Gringe B. Herpesviruses: latency and reactivation- viral strategies and host response. J Oral Microbiol. 2013;25(5).
  14. 14.
    Gilden D, Cohrs R, Mahalingam R. Clinical and molecular pathogenesis of varicella virus infection. Viral Immunol. 2004;16(3):243–58.Google Scholar
  15. 15.
    Cohen J. Herpes zoster. N Engl J Med. 2013;369:255–63.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Greenberg MS. Ulcerative, vesicular, and bullous lesions. In: Greenberg MS, Glick M, editors. Burket’s oral medicine: diagnosis and treatment. 10th ed. Ontario: Decker; 2003. p. 50–84.Google Scholar
  17. 17.
    Manjunath BR, Chidambar YS, Telkar S, Japatti S, Choudary L, Dodamani A. Oral complications of herpes zoster infection- report of 3 cases. Int J Dent Clin. 2010;2(4):70–3.Google Scholar
  18. 18.
    Srikrishna K, Prabhat MPV, Balmuri P, Sudhakar S, Ramaraju D. Herpes zoster: report of a treated case with review of literature. J Ind Acad Oral Med Radiol. 2012;24(1):51–5.Google Scholar
  19. 19.
    Hoyt B, Bhawan J. Histological spectrum of cutaneous herpes infections. Am J Dermatopathol. 2014;36(8):609–19.PubMedGoogle Scholar
  20. 20.
    Wood M, Johnson R, McKendrick M, Taylor J, Mandal B, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330:896–900.PubMedGoogle Scholar
  21. 21.
    Lapolla W, Digiorgio C, Haitz K, Magel G, Grady J, Lu W, Tyring S. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacylcovir in patients with acute herpes zoster: open-label study. Arch Dermatol. 2011;147(8):901–7.PubMedGoogle Scholar
  22. 22.
    Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin N Am. 1996;10(3):571–81.Google Scholar
  23. 23.
    Kilgore PE, Kruszon-Moran D, Seward JF, Jumaan A, Van Loon FP, Forghani B, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(Suppl 1):111–8.Google Scholar
  24. 24.
    Finger R, Hughes JP, Meade BJ, Pelletier AR, Palmer CT. Age-specific incidence of chickenpox. Public Health Rep. 1994;109(6):750–5.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics. 2008;122(3):e744–51.PubMedGoogle Scholar
  26. 26.
    Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis. 2011;203(3):312–5.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Arvin A. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3):361–81.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Heerden V. Oral manifestations of viral infections. S A Fam Pract. 2006;48(8):20–4.Google Scholar
  29. 29.
    Na SY, Son YM, Lee HY, Baek JO, Roh JY, Lee JR. A case of varicella combined with hand-foot-mouth disease in a healthy child. Ann Dermatol. 2009;21(1):98–101.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Kolokotronis A, Louloudiadis K, Fotiou G, Matiais A. Oral manifestations of infections due to varicella zoster virus in otherwise healthy children. J Clin Pediatr Dent. 2001;25(2):107–12.PubMedGoogle Scholar
  31. 31.
    American Academy of Pediatrics Committee on Infectious Diseases. The use of oral acyclovir in otherwise healthy children with varicella. Pediatrics. 1993;91(3):674–6.Google Scholar
  32. 32.
    Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye’s syndrome in the United States from 1981 through 1997. N Engl J Med. 1999;340:1377–82.PubMedGoogle Scholar
  33. 33.
    Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC 3rd. Treatment of adult varicella with oral acyclovir: a randomized, placebo-controlled trial. Ann Intern Med. 1992;117(5):358–63.PubMedGoogle Scholar
  34. 34.
    Repass G, Palmer WC, Stancampiano FF. Hand, foot, and mouth disease: identifying and managing an acute viral syndrome. Cleve Clin J Med. 2014;8199:537–43.Google Scholar
  35. 35.
    Downing C, Ramirez-Fort MK, Doan HQ, Benoist F, Oberste MS, Khan F, et al. Coxsackievirus A6 associated hand, foot and mouth disease in adults: clinical presentation and review of the literature. J Clin Virol. 2014;60:381–6.PubMedGoogle Scholar
  36. 36.
    Stewart CL, Chu EY, Introcaso CE, Schaffer A, James WD. Coxsackievirus A6-induced hand-foot-mouth disease. JAMA Dermatol. 2013;149(12):1419–21.PubMedGoogle Scholar
  37. 37.
    Mehta KI, Mahajan VK. Hand foot and mouth disease. Indian Pediatr. 2010;46:345–6.Google Scholar
  38. 38.
    Slots J. Oral viral infections of adults. Periodontology. 2000;49:60–86.Google Scholar
  39. 39.
    De Carvalho CH, De Andrade AL, de Oliverira DH, Lima E, de Silveira EJ, de Medeiros AM. Intraoral molluscum contagiosum in a young immunocomputent patient. Oral Maxillofacial Pathol. 2012;114(1):e57–60.Google Scholar
  40. 40.
    Dohil MA, Lin P, Lee J, et al. The epidemiology of molluscum contagiosum in children. J Am Acad Dermatol. 2006;54:47–54.PubMedGoogle Scholar
  41. 41.
    Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361:2046–55.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Braue A, Ross G, Varigos G, Kelly H. Epidemiology and impact of childhood molluscum contagiosum: a case series and critical review of the literature. Pediatr Dermatol. 2005;22:287–94.PubMedGoogle Scholar
  43. 43.
    Kreimer AR, Bhatia RK, Messeguer AL, González P, Herrero R, Giuliano AR. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis. 2010;37:386–91.PubMedGoogle Scholar
  44. 44.
    Chung C, Bagheri A, Gypsyamber D. Epidemiology of oral human papillomavirus. Oral Oncol. 2014;50:364–9.PubMedGoogle Scholar
  45. 45.
    Grce M, Marinka M. Human papillomavirus-associated diseases. Clin Dermatol. 2014;32:253–8.PubMedGoogle Scholar
  46. 46.
    Pringle G. The role of human papillomavirus in oral disease. Dent Clin N Am. 2014;58:385–99.PubMedGoogle Scholar
  47. 47.
    Syrjanen S. Human papillomavirus infections and oral tumors. Med Microbiol Immunol. 2003;192:123–8.PubMedGoogle Scholar
  48. 48.
    Nguyen H, McNiece K, Duong A, Khan F. Human papillomavirus infections of the oral mucosa and upper respiratory tract. Curr Prob Dermatol. 2015;45:132–53.Google Scholar
  49. 49.
    Jaiswal R, Pandey M, Shukla M, Dip NB, Kumar M. Condyloma acuminatum of the buccal mucosa. Ear Nose Throat J. 2014;93(6):219–23.PubMedGoogle Scholar
  50. 50.
    Prabhu SR, Wilson DF. Human papillomavirus and oral disease- emerging evidence: a review. Aust Den J. 2013;58:2.Google Scholar
  51. 51.
    Said AK, Leao JC, Fedele S, Porter SR. Focal epithelial hyperplasia—an update. J Oral Pathol Med. 2013;42:435–42.PubMedGoogle Scholar
  52. 52.
    García-Corona C, Vega-Memije E, Mosqueda-Taylor A, Yamamoto-Furusho JK, Rodríguez-Carreón AA, Ruiz-Morales JA, et al. Association of HLA-DR4 (DRB1*0404) with human papillomavirus infection in patients with focal epithelial hyperplasia. Arch Dermatol. 2004;140(10):1227–31. Scholar
  53. 53.
    González LV, Gaviria AM, Sanclemente G, Rady P, Tyring SK, Carlos R, et al. Clinical, histopathological and virological findings in patients with focal epithelial hyperplasia from Colombia. Int J Dermatol. 2005;44:274–9.PubMedGoogle Scholar
  54. 54.
    Bennett LK, Hinshaw M. Heck’s disease: diagnosis and susceptibility. Pediatr Dermatol. 2009;26:87–9.PubMedGoogle Scholar
  55. 55.
    Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med. 2010;362(21):1993–2000.PubMedGoogle Scholar
  56. 56.
    Crawford DH, Macsween KF, Higgins CD, Thomas R, McAulay K, Williams H, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis. 2006;43:276–82.PubMedGoogle Scholar
  57. 57.
    Odumade OA, Hogquist KA, Balfour HH. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev. 2011;24(1):193–209.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1:75–82.PubMedGoogle Scholar
  59. 59.
    Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood. 2008;111:1420–7.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Jenson HB. Acute complications of Epstein-Barr virus infectious mononucleosis. Curr Opin Pediatr. 2000;12:263–8.PubMedGoogle Scholar
  61. 61.
    Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician. 2004;70:1279–87.PubMedGoogle Scholar
  62. 62.
    World Health Organization. Core Epidemiological Slides: HIV/AIDS Estimates; 2014. Powerpoint presentation available from: Accessed 19 Oct 2014.
  63. 63.
    Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2011. In: HIV surveillance supplemental report, vol. 18(5); 2013.Google Scholar
  64. 64.
    Quinn TC. Acute primary HIV infection. JAMA. 1997;278:58.PubMedGoogle Scholar
  65. 65.
    Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory testing for the diagnosis of HIV infection: updated recommendations; 2014. Accessed 8 Oct 2014.
  66. 66.
    Patton LL, Phelan JA, Ramos-Gomez FJ, Nittayananta W, Shiboski CH, Mbuguye TL. Prevalence and classification of HIV- associated oral lesions. Oral Dis. 2002;8(Suppl 2):98–109.PubMedGoogle Scholar
  67. 67.
    Axell T, Azul AM, Challacombe S, Ficcara G, Flint S, Greenspan D. Classification and diagnostic criteria for oral lesions in HIV infection. EC-clearinghouse on oral problems related to HIV infection and WHO collaborating centre on oral manifestations of the immunodeficiency virus. J Oral Pathol Med. 1993;22(7):289–91.Google Scholar
  68. 68.
    Lifson AR, Hilton JF, Westenhouse JL, Canchola AJ, Samuel MC, Katz MH, et al. Time from HIV seroconversion to oral candidiasis or hairy leukoplakia among homosexual and bisexual men enrolled in three prospective cohorts. AIDS. 1994;8:73–9.PubMedGoogle Scholar
  69. 69.
    Patton LL, van der Horst C. Oral infections and other manifestations of HIV disease. Infect Dis Clin N Am. 1999;13(4):879–900.Google Scholar
  70. 70.
    Triantos D, Porter SR, Scully C, Teo CG. Oral hairy leukoplakia: clinicopathologic features, pathogenesis, diagnosis, and clinical significance. Clin Infect Dis. 1997;25:1392–6.PubMedGoogle Scholar
  71. 71.
    Bhandarkar SS, MacKelfresh J, Fried L, Arbiser JL. Targeted therapy of oral hairy leukoplakia with gentian violet. J Am Acad Dermatol. 2008;58:711–2.PubMedGoogle Scholar
  72. 72.
    Braz-Silva P, Santos R, Schussel J, Gallottini M. Oral hairy leukoplakia diagnosis by Epstein–Barr virus in situ hybridization in liquid-based cytology. Cytopathology. 2013;25(1):21–6. Scholar
  73. 73.
    Greenspan JS, Greenspan D. HIV-related oral disease. Lancet. 1996;348:729–33.PubMedGoogle Scholar
  74. 74.
    Patton LL. Oral lesions associated with human immunodeficiency virus disease. Dent Clin N Am. 2013;57(4):673–98.PubMedGoogle Scholar
  75. 75.
    Tappuni AR, Kovacevic T, Shirlaw PJ, Challacombe SJ. Clinical assessment of disease severity in recurrent aphthous stomatitis. J Oral Pathol Med. 2013;42:635–41.PubMedGoogle Scholar
  76. 76.
    Kerr A, Ship J. Management strategies for HIV-associated aphthous stomatitis. Am J Clin Dermatol. 2003;4(10):669–80.PubMedGoogle Scholar
  77. 77.
    Reichart PA. Oral ulcerations in HIV infection. Oral Dis. 1997;3(Suppl 1):180–2.Google Scholar
  78. 78.
    American Society of Hematology. 2011 clinical practice guideline on the evaluation and management of immune thrombocytopenia; 2011. Accessed 21 Oct 2014.
  79. 79.
    Bettaieb A, Fromont P, Louache F, Osksenhendler E, Vainchenker W, Duédari N, et al. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura. Blood. 1992;80:162–9.PubMedGoogle Scholar
  80. 80.
    Reid E. Hematologic manifestations of acquired immunodeficiency syndrome. In: Lichtman MA, Kipps TJ, Seligsohn U, Kaushansky, editors. Williams hematology. 8th ed. China: McGraw-Hill; 2010. p. 1175–99.Google Scholar
  81. 81.
    Ambler K, Vickars L, Leger C, Foltz L, Montaner JS, Harris M, et al. Clinical features, treatment and outcome of HIV-associated immune thrombocytopenia in the HAART era. Adv Hematol. 2012;2012:910–54. Scholar
  82. 82.
    Chapple I, Hamburger J. The significance of oral health in HIV disease. Sex Transm Infect. 2000;76(4):236–43. Scholar
  83. 83.
    Kazi S, Cohen PR, Williams F, Schempp R, Reveille JD. The diffuse infiltrative lymphocytosis syndrome: clinical and immunogenetic features in 35 patients. AIDS. 1996;10(4):385–91.PubMedGoogle Scholar
  84. 84.
    Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM. Molecular genetics of Kaposi’s sarcoma associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev. 2003;67:175–212.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Bohlius J, Valeri F, Maskew M, Prozesky H, Prozesky H, Garone D, Sengayi M, et al. Kaposi’s sarcoma in HIV-infected patients in South Africa: multicohort study in the antiretroviral therapy era. Int J Cancer. 2014;135:2644–52. Scholar
  86. 86.
    Schwartz R, Micali G, Nasca M, Scuderi L. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol. 2008;59(2):179–206.PubMedGoogle Scholar
  87. 87.
    Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A. 1996;93:14862–7.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Cattani P, Capuano M, Cerimele F, La Parola IL, Santangelo R, Masini C, et al. Human herpesvirus 8 seroprevalence and evaluation of nonsexual transmission routes by detection of DNA in clinical specimens from human immunodeficiency virus-seronegative patients from central and southern Italy, with and without Kaposi’s sarcoma. J Clin Microbiol. 1999;37:1150–3.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Schwartz RA. Kaposi’s sarcoma: advances and perspectives. J Am Acad Dermatol. 1996;34:804–14.PubMedGoogle Scholar
  90. 90.
    Lemlich G, Schwam L, Lebwohl M. Kaposi’s sarcoma and acquired immunodeficiency syndrome: postmortem findings in twenty-four cases. J Am Acad Dermatol. 1987;16:319–25.PubMedGoogle Scholar
  91. 91.
    World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-Related disease in adults and children; 2006. Accessed 19 Oct 2014.
  92. 92.
    Feller L, Jadwat Y, Raubenheimer EJ. Kaposi sarcoma and calcium channel blocker-induced gingival enlargement occurring simultaneously: review of the literature and report of a case. Oral Biosci Med. 2004;4:291–7.Google Scholar
  93. 93.
    Pantanowitz L, Khammissa R, Lemmer J, Feller L. Oral HIV-associated Kaposi sarcoma. J Oral Pathol Med. 2013;42:201–7.PubMedGoogle Scholar
  94. 94.
    Fatahzadeh M, Schwartz RA. Oral Kaposi’s sarcoma: a review and update. Int J Dermatol. 2013;52:666–72.PubMedGoogle Scholar
  95. 95.
    Vanni T, Sprinz E, Machado MW, Santana Rde C, Fonseca BA, et al. Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives. Cancer Treat Rev. 2006;32:445–55. Scholar
  96. 96.
    Doumas S, Vladikas A, Papagianni M, Kolokotronis A. Human cytomegalovirus-associated oral and maxillo-facial disease. Clin Microbiol Infect. 2007;13:557–9.PubMedGoogle Scholar
  97. 97.
    Lazzarotto T, Guerra B, Gabrielli L, Lanari M, Landini MP. Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. Clin Microbiol Infect. 2011;17:1285–93. Scholar
  98. 98.
    Stoopler ET, Greenberg MS. Update on herpesvirus infections. Dent Clin N Am. 2003;47(4):517–32.PubMedGoogle Scholar
  99. 99.
    Bruminhent J, Razonable R. Management of cytomegalovirus infection and disease in liver transplant recipients. World J Hepatol. 2014;6(6):370–83.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Taylor GH. Cytomegalovirus. Am Fam Physician. 2003;67(3):519–24.PubMedGoogle Scholar
  101. 101.
    Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant. 2013;13:24–40.PubMedGoogle Scholar
  102. 102.
    Whitcup SM. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA. 2000;283:653–7.PubMedGoogle Scholar
  103. 103.
    Kaplan J, Masur H, Holmes K. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2002;51(08):1–46.Google Scholar
  104. 104.
    Dauden E, Fernandez-Buezo G, Fraga J, Cardenoso L, Garcia-Diez A. Mucocutaneous presence of cytomegalovirus associated with human immunodeficiency virus infection. Arch Dermatol. 2000;137:443–8.Google Scholar
  105. 105.
    Flaitz C, Nichols M, Hicks M. Herpesviridae-associated persistent mucocutaneous ulcers in acquired immunodeficiency syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81(4):433–41.PubMedGoogle Scholar
  106. 106.
    Drutz JE. Rubella. Pediatr Rev. 2010;31(3):129–30.PubMedGoogle Scholar
  107. 107.
    Castillo-Solorzano C, Matus CR, Flannery B, Marsigli C, Tambini G, Andrus JK. The Americas: paving the road toward global measles eradication. J Infect Dis. 2011;204(Suppl 1):270–8.Google Scholar
  108. 108.
    Centers for Disease Control and Prevention (CDC). Nationwide rubella epidemic – Japan, 2013. MMWR Morb Mortal Wkly Rep. 2013;62:457.Google Scholar
  109. 109.
    Banatvala JE, Brown DW. Rubella. Lancet. 2004;363:1127–37.PubMedGoogle Scholar
  110. 110.
    Baden H, Provan J. Oral lesion of rubella. Arch Dermatol. 1976;112(12):1973.Google Scholar
  111. 111.
    Thomas HI, Morgan-Capner P, Cradock-Watson JE, Enders G, Best JM, O’Shea S. Slow maturation of IgG1 avidity and persistence of specific IgM in congenital rubella: implications for diagnosis and immunopathology. J Med Virol. 1993;41:196.PubMedGoogle Scholar
  112. 112.
    Dayan GH, Quinlisk MP, Parker AA, Barskey AE, Harris ML, Schwartz JM, et al. Recent resurgence of mumps in the United States. N Engl J Med. 2008;358:1580–9.PubMedGoogle Scholar
  113. 113.
    Whitaker JA, Poland GA. Measles and mumps outbreaks in the United States: think globally, vaccinate locally. Vaccine. 2014;32:4703–4.PubMedGoogle Scholar
  114. 114.
    Hviid A, Rubin S, Muhlemann K. Mumps. Lancet. 2008;371:932–44.PubMedGoogle Scholar
  115. 115.
    Richardson M, Elliman D, Maguire H, Simpson J, Nicoll A. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J. 2001;20:380–91.PubMedGoogle Scholar
  116. 116.
    Ennis FA, Jackson D. Isolation of virus during the incubation period of mumps infection. J Pediatr. 1968;72:536–7.PubMedGoogle Scholar
  117. 117.
    Sallberg M. Oral viral infections of children. Periodontology. 2000;49:87–95.Google Scholar
  118. 118.
    Grabowsky M. The beginning of the end of the measles and rubella. Arch Pediatr Adolesc Med. 2014;168(2):108–9.Google Scholar
  119. 119.
    Centers for Disease Control and Prevention (CDC). Brief report: update: mumps activity – United States, January 1-October 7, 2006. MMWR Morb Mortal Wkly Rep. 2006;55(42):1152.Google Scholar
  120. 120.
    Duke T, Mgone CS. Measles: not just another viral exanthem. Lancet. 2003;361:763–73.PubMedGoogle Scholar
  121. 121.
    Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9:291–300.PubMedPubMedCentralGoogle Scholar
  122. 122.
    Moss MJ, Griffin DE. Measles. Lancet. 2012;379:153–64.PubMedGoogle Scholar
  123. 123.
    Battegay R, Itin C, Itin P. Dermatological signs and symptoms of measles: a prospective case series and comparison with the literature. Dermatology. 2012;224:1–4.PubMedGoogle Scholar
  124. 124.
    Silverman S, Miller C. Diagnosis and treatment of viral infections. Oral Maxillofac Surg Clin N Am. 2003;15(1):79–89.Google Scholar
  125. 125.
    Kayal L, Jayachandran S, Singh K. Idiopathic thrombocytopenic purpura. Contemp Clin Dent. 2014;5(3):410–4.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Restrepo CS, Ocazionez D. Kaposi’s sarcoma: imaging overview. Semin Ultrasound CT MRI. 2011;32(5):465–9.Google Scholar
  127. 127.
    Patel LM, Lambert PJ, Gagna CE, Maghari A, Clark Lambert W. Cutaneous signs of systemic disease. Clin Dermatol. 2011;28(5):511–2.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Danielle N. Brown
    • 1
  • Ramya Kollipara
    • 2
    Email author
  • Stephen Tyring
    • 3
  1. 1.Department of PediatricsMassachusetts General Hospital for ChildrenBostonUSA
  2. 2.DermatologyCosmetic Laser DermatologySan DiegoUSA
  3. 3.Department of DermatologyUniversity of Texas Health Sciences Center at HoustonHoustonUSA

Personalised recommendations